{
    "hands_on_practices": [
        {
            "introduction": "The cornerstone of managing Erythema Multiforme (EM) is accurate clinical diagnosis, which hinges on differentiating it from severe mimics like Stevens-Johnson Syndrome (SJS) and more common rashes like morbilliform drug eruptions. This first practice challenges you to apply the strict definitions of lesion morphology, distribution, and associated signs to a classic clinical vignette. Mastering this process is crucial for making timely and correct diagnostic decisions, directly impacting patient management and prognosis .",
            "id": "4438837",
            "problem": "A 24-year-old man presents with an acute pruritic eruption that began on the backs of his hands and feet and has spread to the extensor forearms and legs over 24 hours. The trunk is largely spared. Ten days ago he started amoxicillin for acute sinusitis. He denies fever, malaise, ocular symptoms, genital discomfort, or oral pain. On examination, there are multiple well-demarcated “target” lesions with three concentric zones of color change and a central dusky area on the dorsal hands and extensor forearms; similar lesions are on the feet. There are no bullae, no erosions, and no appreciable mucosal involvement. Lateral pressure on perilesional skin does not induce epidermal sloughing (Nikolsky sign is negative). \n\nUsing core clinical definitions of erythema multiforme (EM) and morbilliform drug eruption, and the mechanistic basis for the Nikolsky sign, which of the following is the most likely classification of this eruption and the best justification for it?\n\nA. Erythema multiforme (EM) minor triggered by drug exposure; the presence of true three-zone target lesions with acral predominance and a negative Nikolsky sign favors EM over a morbilliform exanthem, which typically presents with diffuse blanchable macules and papules starting on the trunk without true targets.\n\nB. Morbilliform drug eruption due to amoxicillin; the approximately 10-day latency and antibiotic exposure are decisive, and morbilliform eruptions frequently feature true target lesions with acral onset and trunk sparing.\n\nC. Stevens-Johnson syndrome (SJS) secondary to amoxicillin; targetoid lesions in the setting of a new drug exposure point to SJS, and a negative Nikolsky sign is characteristic.\n\nD. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS); the timing after drug initiation and widespread eruption with systemic immune activation best explain the findings even without mucosal disease.\n\nE. Erythema multiforme (EM) major; the presence of target lesions with acral predominance implies EM with significant mucosal involvement even if mucosal symptoms are not reported.",
            "solution": "The user wants a meticulous and exacting professor in STEM to solve a dermatology problem. The process must start with a rigorous validation of the problem statement, followed by a detailed, principle-based derivation of the solution and a thorough evaluation of each option. All mathematical and symbolic entities must be in LaTeX.\n\n### Step 1: Extract Givens\n- **Patient**: A 24-year-old man.\n- **Chief Complaint**: Acute pruritic eruption.\n- **History of Present Illness**: Onset on the backs of hands and feet, spreading to extensor forearms and legs over 24 hours. Trunk is largely spared. Started amoxicillin for acute sinusitis 10 days prior to onset.\n- **Review of Systems**: Denies fever, malaise, ocular symptoms, genital discomfort, or oral pain.\n- **Physical Examination**:\n    - **Lesions**: Multiple well-demarcated “target” lesions with 3 concentric zones of color change and a central dusky area.\n    - **Distribution**: Dorsal hands, extensor forearms, and feet.\n    - **Other findings**: No bullae, no erosions, no appreciable mucosal involvement.\n    - **Special Tests**: Lateral pressure on perilesional skin does not induce epidermal sloughing (Nikolsky sign is negative).\n- **Task**: Using core clinical definitions, classify the eruption and provide the best justification.\n\n### Step 2: Validate Using Extracted Givens\nThe problem statement is a clinical vignette that requires the application of established diagnostic criteria from dermatology.\n\n- **Scientific Grounding**: The problem is scientifically grounded. The clinical presentation, including the description of \"target\" lesions, acral distribution, drug history (amoxicillin), time latency (10 days), and the negative Nikolsky sign, describes a classic scenario in dermatology. The concepts of Erythema Multiforme (EM), Stevens-Johnson Syndrome (SJS), morbilliform eruption, and Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) are well-defined medical conditions. The mechanism of the Nikolsky sign (loss of epidermal coherence) is a fundamental concept in blistering skin diseases.\n- **Well-Posedness**: The problem is well-posed. The clinical data provided are sufficient to arrive at a \"most likely\" diagnosis among the choices by systematically applying standard diagnostic criteria. The question asks for a classification and justification, for which a unique and stable answer exists based on the provided evidence.\n- **Objectivity**: The problem is objective. It presents clinical findings in precise, unbiased language (e.g., \"well-demarcated\", \"3 concentric zones\", \"no appreciable mucosal involvement\").\n\nThe problem does not exhibit any flaws such as scientific unsoundness, missing information, contradiction, or ambiguity. All terms are standard in the field of dermatology.\n\n### Step 3: Verdict and Action\nThe problem statement is **valid**. A solution will be derived.\n\n### Derivation of Solution\nThe diagnosis is established by systematically analyzing the key clinical features in the context of the differential diagnoses provided.\n\n1.  **Lesion Morphology**: The pathognomonic finding is \"multiple well-demarcated 'target' lesions with three concentric zones of color change and a central dusky area\". These are described as \"true\" or \"typical\" target lesions. This specific morphology is the hallmark of Erythema Multiforme (EM). Other conditions like SJS may have \"atypical targets\" or \"targetoid\" lesions, which are usually flat, have only 2 zones, and a poorly defined border. Morbilliform eruptions consist of macules and papules (\"measles-like\"), not target lesions.\n\n2.  **Lesion Distribution**: The eruption has an acral (hands and feet) and extensor (forearms and legs) distribution, with the trunk being \"largely spared\". This distribution is classic for EM. In contrast, morbilliform drug eruptions typically begin on the trunk and spread centrifugally.\n\n3.  **Mucosal Involvement**: The patient has \"no appreciable mucosal involvement\" and denies oral, ocular, or genital symptoms. EM is sub-classified based on mucosal involvement. EM minor is defined by the absence of or only mild involvement of one mucosal surface. EM major is defined by significant involvement (e.g., erosions, bullae) of at least one mucosal surface. Stevens-Johnson Syndrome (SJS) is characterized by severe, widespread mucosal erosions, typically affecting two or more sites (e.g., oral, ocular, genital). The complete absence of mucosal disease in this patient points strongly to EM minor and argues definitively against EM major and SJS.\n\n4.  **Systemic Symptoms**: The patient \"denies fever, malaise\". EM minor is typically associated with minimal to no systemic symptoms. In contrast, SJS and DRESS are severe systemic reactions characterized by high fever and profound malaise. The absence of these symptoms is another strong point against SJS and DRESS.\n\n5.  **Nikolsky Sign**: The Nikolsky sign is negative. This sign indicates a plane of cleavage within the epidermis or at the dermal-epidermal junction, where lateral pressure causes the epidermis to slough off. A positive Nikolsky sign is a characteristic and crucial finding in SJS and its more severe variant, Toxic Epidermal Necrolysis (TEN), as it reflects widespread keratinocyte apoptosis and full-thickness epidermal necrosis. Its absence argues against SJS/TEN and is consistent with EM, where the inflammatory process does not typically cause such widespread loss of epidermal cohesion.\n\n6.  **Etiology/Trigger**: The eruption began 10 days after starting amoxicillin. While infections, particularly Herpes Simplex Virus (HSV), are the most common triggers for EM, drugs are the second most common cause. The latency of 7-14 days is typical for a drug-induced hypersensitivity reaction. Therefore, amoxicillin is a very plausible trigger.\n\n**Conclusion of Derivation**: The combination of typical 3-zone target lesions, acral distribution with trunk sparing, absence of mucosal involvement, absence of systemic symptoms, and a negative Nikolsky sign provides a classic and definitive clinical picture of **Erythema Multiforme minor**, likely triggered by amoxicillin exposure.\n\n### Option-by-Option Analysis\n\n**A. Erythema multiforme (EM) minor triggered by drug exposure; the presence of true three-zone target lesions with acral predominance and a negative Nikolsky sign favors EM over a morbilliform exanthem, which typically presents with diffuse blanchable macules and papules starting on the trunk without true targets.**\n- This option correctly identifies the condition as EM minor and the probable trigger as drug exposure. The justification is precise and accurate. It correctly identifies the pathognomonic features of EM (true target lesions, acral distribution) and contrasts them correctly with the features of a morbilliform eruption (maculopapular, truncal onset). It also correctly notes the significance of the negative Nikolsky sign.\n- **Verdict**: **Correct**.\n\n**B. Morbilliform drug eruption due to amoxicillin; the approximately 10-day latency and antibiotic exposure are decisive, and morbilliform eruptions frequently feature true target lesions with acral onset and trunk sparing.**\n- This option incorrectly identifies the eruption type. While the timing and trigger are plausible for a drug eruption, the statement that \"morbilliform eruptions frequently feature true target lesions with acral onset and trunk sparing\" is factually incorrect. A morbilliform eruption lacks true target lesions and typically starts on the trunk. The morphology and distribution described in the case are inconsistent with a morbilliform eruption.\n- **Verdict**: **Incorrect**.\n\n**C. Stevens-Johnson syndrome (SJS) secondary to amoxicillin; targetoid lesions in the setting of a new drug exposure point to SJS, and a negative Nikolsky sign is characteristic.**\n- This option is incorrect for multiple reasons. First, SJS is defined by significant mucosal erosions, which are explicitly absent. Second, the lesions in SJS are typically \"atypical targets,\" not the classic 3-zone targets described. Third, the statement that a \"negative Nikolsky sign is characteristic\" of SJS is false; a positive Nikolsky sign is a hallmark of SJS/TEN.\n- **Verdict**: **Incorrect**.\n\n**D. Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS); the timing after drug initiation and widespread eruption with systemic immune activation best explain the findings even without mucosal disease.**\n- This option is incorrect. DRESS is a systemic illness defined by fever, hematologic abnormalities (e.g., eosinophilia), and internal organ involvement. This patient has no systemic symptoms (\"denies fever, malaise\"), and there is no information to suggest systemic involvement. Furthermore, the eruption in DRESS is most commonly morbilliform, not characterized by true target lesions.\n- **Verdict**: **Incorrect**.\n\n**E. Erythema multiforme (EM) major; the presence of target lesions with acral predominance implies EM with significant mucosal involvement even if mucosal symptoms are not reported.**\n- This option is incorrect. It rightly identifies the skin findings as EM, but incorrectly classifies it as EM major. The classification of EM major versus EM minor is based entirely on the presence or absence of significant mucosal disease. The claim that skin findings can *imply* mucosal involvement in the face of direct clinical evidence to the contrary (no symptoms, no findings on exam) is clinically and logically invalid. The absence of mucosal disease defines this as EM minor.\n- **Verdict**: **Incorrect**.",
            "answer": "$$\\boxed{A}$$"
        },
        {
            "introduction": "While clinical acumen is paramount, histopathology provides definitive confirmation of Erythema Multiforme and offers deeper insight into its pathogenesis. This exercise moves from the macroscopic to the microscopic, asking you to interpret biopsy findings based on an understanding of the underlying immunopathology. By learning to recognize the characteristic interface dermatitis of EM and distinguish it from its simulators based on specific cellular infiltrates, you can solidify the diagnosis and appreciate the connection between clinical signs and cellular events .",
            "id": "4438793",
            "problem": "A 32-year-old patient presents with abrupt-onset acral targetoid lesions 48 hours after a labial herpes simplex flare. There is no history of new medications in the past 4 weeks. A punch biopsy from a typical targetoid lesion shows an interface pattern characterized by vacuolar alteration of the basal layer, scattered dyskeratotic keratinocytes at multiple epidermal levels, minimal spongiosis, compact orthokeratosis, and a superficial perivascular lymphocytic infiltrate. Eosinophils are rare, with a mean of 1 cell per $400\\times$ high-power field (HPF) and a maximum of 2 cells per $400\\times$ HPF across 10 HPFs. There is no significant parakeratosis, no leukocytoclastic vasculitis, and no full-thickness epidermal necrosis. Using the definitions of interface dermatitis, the immunopathologic mechanisms of Type IV hypersensitivity, and well-tested histopathologic observations about cell-type recruitment, derive a histologic decision rule that distinguishes erythema multiforme (EM) from a morbilliform drug eruption, and apply it to this case to determine the more likely diagnosis.\n\nWhich option most accurately states such a decision rule and its correct application to the biopsy described?\n\nA. In an interface dermatitis, vacuolar basal damage with scattered necrotic keratinocytes at multiple levels accompanied by minimal eosinophils (e.g., $2$ per $400\\times$ HPF) favors erythema multiforme; prominent eosinophils (e.g., $\\ge 5$ per $400\\times$ HPF) with spongiosis and parakeratosis favors a drug eruption. Applied here, the findings favor erythema multiforme.\n\nB. Parakeratosis and neutrophil microabscesses are decisive for erythema multiforme, whereas eosinophils are rarely seen in drug eruptions; therefore, the absence of parakeratosis and neutrophils still supports erythema multiforme in this biopsy.\n\nC. Full-thickness epidermal necrosis is the sine qua non of erythema multiforme; when absent, the pattern is more consistent with a drug eruption.\n\nD. A dense, band-like lichenoid infiltrate with saw-toothing of rete ridges and numerous Civatte bodies, in the complete absence of eosinophils, defines erythema multiforme; because the biopsy shows vacuolar change rather than a dense band-like infiltrate, a drug eruption is more likely.\n\nE. Dermal mucin accumulation with perivascular plasma cells and low eosinophil counts (e.g., $5$ per $400\\times$ HPF) favors erythema multiforme; applied here, the findings support erythema multiforme.",
            "solution": "The task is to first validate the problem statement, and if valid, derive a histologic decision rule to distinguish erythema multiforme (EM) from a morbilliform drug eruption and apply it to the given case. This derivation must be based on the principles of interface dermatitis, Type IV hypersensitivity immunopathology, and established histopathologic findings.\n\n### Problem Validation\n\n**Step 1: Extract Givens**\n\n*   **Patient Age**: 32 years\n*   **Clinical Onset**: Abrupt\n*   **Lesion Morphology**: Acral targetoid lesions\n*   **Temporal Association**: 48 hours after a labial herpes simplex flare\n*   **Medication History**: No new medications in the past 4 weeks\n*   **Biopsy Site**: Typical targetoid lesion\n*   **Histopathology**:\n    *   **Overall Pattern**: Interface pattern\n    *   **Basal Layer**: Vacuolar alteration\n    *   **Keratinocytes**: Scattered dyskeratotic keratinocytes at multiple epidermal levels\n    *   **Spongiosis**: Minimal\n    *   **Stratum Corneum**: Compact orthokeratosis\n    *   **Infiltrate**: Superficial perivascular lymphocytic infiltrate\n    *   **Eosinophils**: Rare; mean of 1 cell per $400\\times$ high-power field (HPF); maximum of 2 cells per $400\\times$ HPF across 10 HPFs.\n    *   **Negative Findings**: No significant parakeratosis, no leukocytoclastic vasculitis, no full-thickness epidermal necrosis.\n\n**Step 2: Validate Using Extracted Givens**\n\n1.  **Scientific Groundedness**: The problem is scientifically grounded. The clinical presentation (targetoid lesions following a herpes simplex flare) is the quintessential trigger and appearance of erythema multiforme. The histopathologic features described are the textbook findings for classic EM. The differential diagnosis with a morbilliform drug eruption is a common and important real-world challenge in dermatopathology. The underlying immunopathologic principles involving Type IV hypersensitivity are correctly invoked.\n2.  **Well-Posedness**: The problem is well-posed. It provides sufficient clinical and pathological data to allow for a reasoned differential diagnosis. The question is specific and asks for the derivation and application of a diagnostic rule.\n3.  **Objectivity**: The language is precise and objective, using standard medical and histopathological terminology.\n\n**Step 3: Verdict and Action**\n\nThe problem statement is valid. It is scientifically sound, correctly structured, and represents a standard diagnostic reasoning task in medicine. The solution process will now proceed.\n\n### Derivation of a Decision Rule and Application\n\n**1. Foundational Principles**\n\n*   **Interface Dermatitis**: This represents an inflammatory process at the dermal-epidermal junction (DEJ). Erythema multiforme is the archetypal example of the **vacuolar** (or hydropic) subtype, characterized by vacuolization of basal keratinocytes and a typically sparse-to-moderate inflammatory infiltrate. This is distinct from the **lichenoid** subtype, which features a dense, band-like infiltrate that obscures the DEJ.\n*   **Immunopathology**: Both EM and morbilliform drug eruptions are forms of Type IV (delayed-type) hypersensitivity.\n    *   **Erythema Multiforme (HSV-associated)**: This is understood to be a Type IVc hypersensitivity reaction. Herpes simplex virus (HSV) DNA fragments are transported to keratinocytes. Virus-specific CD8$^+$ cytotoxic T-lymphocytes (CTLs) recognize these viral antigens on keratinocyte surfaces and induce apoptosis (programmed cell death). This targeted, cell-by-cell killing results in scattered single necrotic keratinocytes (dyskeratosis) at all levels of the epidermis. The inflammatory response is dominated by lymphocytes.\n    *   **Morbilliform Drug Eruption**: These are often a mix of Type IVb and Type IVc reactions. The Type IVc component involves drug-specific CTLs causing keratinocyte apoptosis, similar to EM. However, a key distinction is the frequent presence of a Type IVb component, which involves drug-specific CD4$^+$ T-helper 2 (Th2) cells. Th2 cells release cytokines such as Interleukin-4 (IL-4), Interleukin-5 (IL-5), and Interleukin-13 (IL-13). IL-5 is a potent chemoattractant and activator for eosinophils. The recruitment of eosinophils is therefore a major clue for a drug-induced etiology.\n*   **Histopathologic Observations**:\n    *   **Erythema Multiforme**: Key features include: (1) a vacuolar interface dermatitis; (2) scattered, solitary necrotic keratinocytes at various epidermal levels (satellite cell necrosis); (3) a predominantly lymphocytic superficial perivascular infiltrate; (4) a notable **paucity of eosinophils**; (5) often minimal spongiosis and compact orthokeratosis. Confluent or full-thickness epidermal necrosis is the hallmark of Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis (SJS/TEN), a separate entity.\n    *   **Morbilliform Drug Eruption**: These eruptions also show a superficial perivascular infiltrate and can have an interface component with vacuolar change and necrotic keratinocytes. However, distinguishing features include: (1) the frequent presence of **numerous eosinophils** in the infiltrate; (2) often more prominent spongiosis and parakeratosis compared to EM.\n\n**2. Derived Histologic Decision Rule**\n\nBased on these principles, a robust decision rule for an interface dermatitis is as follows: The presence of prominent vacuolar interface change with scattered necrotic keratinocytes, accompanied by a predominantly lymphocytic infiltrate with very few or no eosinophils (e.g., a mean count $2$ per $400\\times$ HPF), strongly favors a diagnosis of erythema multiforme. Conversely, the presence of a significant number of eosinophils in the infiltrate (e.g., a mean count $\\ge 5$ per $400\\times$ HPF), often with more conspicuous spongiosis or parakeratosis, strongly points to a drug eruption.\n\n**3. Application to the Present Case**\n\n*   The biopsy shows a **vacuolar interface pattern** with **scattered dyskeratotic keratinocytes at multiple levels**. This is a core feature of EM.\n*   The infiltrate is lymphocytic and superficial perivascular.\n*   Crucially, eosinophils are **rare**, with a mean of 1 cell per $400\\times$ HPF. This low count strongly argues against a drug eruption and for EM.\n*   Other findings like minimal spongiosis, compact orthokeratosis, and absence of significant parakeratosis further align with the classic picture of EM.\n*   The absence of full-thickness necrosis correctly places the diagnosis within the spectrum of classic EM, not SJS/TEN.\n*   The clinical history of a preceding HSV flare provides near-definitive corroborating evidence.\n\nTherefore, applying the derived rule to the given biopsy, the findings are overwhelmingly in favor of erythema multiforme.\n\n### Evaluation of Options\n\n*   **A. In an interface dermatitis, vacuolar basal damage with scattered necrotic keratinocytes at multiple levels accompanied by minimal eosinophils (e.g., $2$ per $400\\times$ HPF) favors erythema multiforme; prominent eosinophils (e.g., $\\ge 5$ per $400\\times$ HPF) with spongiosis and parakeratosis favors a drug eruption. Applied here, the findings favor erythema multiforme.**\n    *   This option presents a decision rule that is perfectly consistent with the one derived from immunopathologic and histopathologic principles. It correctly identifies the key discriminators: the pattern of necrosis and, most importantly, the eosinophil count. The quantitative thresholds provided ($2$ vs. $\\ge 5$) are standard heuristics in dermatopathology. The application is also correct; the patient's biopsy finding of a mean of 1 eosinophil per HPF falls squarely in the EM category.\n    *   **Verdict**: **Correct**.\n\n*   **B. Parakeratosis and neutrophil microabscesses are decisive for erythema multiforme, whereas eosinophils are rarely seen in drug eruptions; therefore, the absence of parakeratosis and neutrophils still supports erythema multiforme in this biopsy.**\n    *   This statement contains multiple factual errors. Parakeratosis and neutrophils are not features of EM. Most critically, the claim that eosinophils are rare in drug eruptions is false; they are a hallmark feature.\n    *   **Verdict**: **Incorrect**.\n\n*   **C. Full-thickness epidermal necrosis is the sine qua non of erythema multiforme; when absent, the pattern is more consistent with a drug eruption.**\n    *   This is incorrect. Full-thickness epidermal necrosis defines SJS/TEN, not classic EM. Its absence is expected in EM. This statement confuses the classification of reactive erythemas.\n    *   **Verdict**: **Incorrect**.\n\n*   **D. A dense, band-like lichenoid infiltrate with saw-toothing of rete ridges and numerous Civatte bodies, in the complete absence of eosinophils, defines erythema multiforme; because the biopsy shows vacuolar change rather than a dense band-like infiltrate, a drug eruption is more likely.**\n    *   This describes the classic features of lichen planus, not erythema multiforme. EM is characterized by a vacuolar interface pattern, which the biopsy shows. To conclude that this vacuolar pattern favors a drug eruption over EM is a direct contradiction of established pathology.\n    *   **Verdict**: **Incorrect**.\n\n*   **E. Dermal mucin accumulation with perivascular plasma cells and low eosinophil counts (e.g., $5$ per $400\\times$ HPF) favors erythema multiforme; applied here, the findings support erythema multiforme.**\n    *   This rule is flawed. While low eosinophils are consistent with EM, dermal mucin and prominent plasma cells are not characteristic features of EM. They are more suggestive of other conditions like lupus erythematosus or syphilis, respectively. The rule is poorly constructed with irrelevant distractors.\n    *   **Verdict**: **Incorrect**.",
            "answer": "$$\\boxed{A}$$"
        },
        {
            "introduction": "Beyond diagnosis, a key aspect of managing recurrent Erythema Multiforme is implementing and evaluating preventive strategies. This final practice shifts the focus to evidence-based medicine, a critical skill for any clinician. Using a hypothetical but clinically relevant scenario involving prophylactic antiviral therapy, you will apply fundamental principles of epidemiology to calculate the Number Needed to Treat (NNT), a powerful metric for quantifying the real-world impact and efficiency of a medical intervention .",
            "id": "4365391",
            "problem": "A cohort of adults with herpes simplex virus-associated Erythema Multiforme (EM) minor is followed for one year to study prophylaxis. In the absence of antiviral prophylaxis, the baseline risk of experiencing at least one clinically significant EM recurrence within one year is $r_{0} = 0.55$. Continuous oral acyclovir prophylaxis acts upstream by suppressing herpes simplex virus reactivation and is observed to confer a relative risk reduction (RRR) of $\\text{RRR} = 0.45$ for having at least one EM recurrence during the same one-year period.\n\nUsing only foundational definitions from clinical epidemiology—namely, event risk, risk under treatment, absolute risk reduction, and the number needed to treat—derive the expression that connects these quantities and compute the number needed to treat (NNT) to prevent one additional EM recurrence over one year with continuous acyclovir. Report the NNT by the conventional rule as the smallest integer greater than or equal to the exact value. Provide the final answer as a single integer with no units.",
            "solution": "The problem is deemed valid as it is scientifically grounded in established principles of clinical epidemiology, is well-posed with sufficient and consistent data, and is expressed in objective, formal language. We may proceed with the solution.\n\nThe problem requires the derivation of an expression connecting several epidemiological quantities and the subsequent calculation of the Number Needed to Treat (NNT). Let us begin by defining the terms based on the provided information and foundational principles.\n\nThe baseline risk, or the risk in the control group (no prophylaxis), is given as $r_0$. This is the Control Event Rate (CER).\n$$\n\\text{CER} = r_0 = 0.55\n$$\nLet $r_t$ be the risk under treatment (acyclovir prophylaxis). This is the Experimental Event Rate (EER).\n$$\n\\text{EER} = r_t\n$$\nThe problem provides the Relative Risk Reduction (RRR), which is defined as the proportional reduction in risk in the experimental group compared to the control group.\n$$\n\\text{RRR} = \\frac{\\text{CER} - \\text{EER}}{\\text{CER}} = \\frac{r_0 - r_t}{r_0}\n$$\nThe value given is $\\text{RRR} = 0.45$.\n\nThe Absolute Risk Reduction (ARR) is the absolute difference in the event rates between the control and experimental groups.\n$$\n\\text{ARR} = \\text{CER} - \\text{EER} = r_0 - r_t\n$$\nThe Number Needed to Treat (NNT) is the reciprocal of the Absolute Risk Reduction. It represents the average number of patients who must be treated to prevent one additional adverse outcome.\n$$\n\\text{NNT} = \\frac{1}{\\text{ARR}}\n$$\nOur first objective is to derive the expression that connects these quantities. We can establish a direct relationship between ARR, RRR, and the baseline risk $r_0$. By substituting the definition of ARR into the formula for RRR, we obtain:\n$$\n\\text{RRR} = \\frac{\\text{ARR}}{\\text{CER}} = \\frac{\\text{ARR}}{r_0}\n$$\nRearranging this equation to solve for ARR gives:\n$$\n\\text{ARR} = r_0 \\times \\text{RRR}\n$$\nNow, we substitute this expression for ARR into the definition of NNT:\n$$\n\\text{NNT} = \\frac{1}{r_0 \\times \\text{RRR}}\n$$\nThis is the derived expression that connects NNT to the baseline risk $r_0$ and the relative risk reduction RRR.\n\nOur second objective is to compute the numerical value of NNT using the provided data. We substitute the given values $r_0 = 0.55$ and $\\text{RRR} = 0.45$ into our derived expression.\nFirst, we calculate the ARR:\n$$\n\\text{ARR} = 0.55 \\times 0.45 = 0.2475\n$$\nNext, we calculate the exact value of NNT:\n$$\n\\text{NNT} = \\frac{1}{\\text{ARR}} = \\frac{1}{0.2475}\n$$\nTo work with this fraction more easily, we can express the decimal as a fraction: $0.2475 = \\frac{2475}{10000}$.\n$$\n\\text{NNT} = \\frac{1}{\\frac{2475}{10000}} = \\frac{10000}{2475}\n$$\nThis fraction can be simplified by dividing the numerator and denominator by their greatest common divisor, which is $25$.\n$$\n\\text{NNT} = \\frac{10000 \\div 25}{2475 \\div 25} = \\frac{400}{99}\n$$\nPerforming the division gives the decimal representation:\n$$\n\\text{NNT} = 4.040404...\n$$\nThe problem states that the NNT should be reported \"by the conventional rule as the smallest integer greater than or equal to the exact value.\" This operation is equivalent to the ceiling function, denoted $\\lceil \\cdot \\rceil$.\n$$\n\\text{NNT}_{\\text{reported}} = \\left\\lceil \\frac{400}{99} \\right\\rceil = \\lceil 4.040404... \\rceil = 5\n$$\nTherefore, the number needed to treat to prevent one additional EM recurrence over one year is $5$.",
            "answer": "$$\\boxed{5}$$"
        }
    ]
}